Zhao X, Fu Y, Peng X
Third People's Hospital of Zhengzhou, Zhengzhou 450000, China.
Zhonghua Xue Ye Xue Za Zhi. 2001 Oct;22(10):536-8.
To report a patients with acute aplastic anemia(AAA) successfully treated with allogeneic peripheral blood stem cell transplantation(allo-PBSCT).
A 30 years old patient with AA received allo-PBSCT from a HLA-compatible sibling donor. PBSCs mobilization regimen was G-GSF 250 micrograms/d x 6. The conditioning regimen included (CTX 50 mg.kg-1.d-1) x 4 and (ATG 10 kg-1.d-01) x 2. 8.97 x 10(8) nucleated cells/kg, 9.20 x 10(6) CD34+ cells/kg, 11.20 x 10(5) CFU-GM/kg were transplanted.
Hematopoietic reconstitution obtained on day 18 after allo-PBSCT. Monitoring of engraftment with three microsatellite markers showed mixed chimerism on day 18 and complete chimerism after day 25. No acute or chronic graft versus host disease (GVHD) occurred. In the follow-up duration of 240 days, the blood and bone marrow pictures were normal and the living status was good.
Allo-PBSCT was an effective therapy in the treatment of acute aplastic anemia.
报告1例急性再生障碍性贫血（AAA）患者通过异基因外周血干细胞移植（allo-PBSCT）成功治疗的病例。
1例30岁的再生障碍性贫血患者接受了来自HLA配型相合的同胞供者的allo-PBSCT。外周血干细胞动员方案为粒细胞集落刺激因子（G-GSF）250微克/天×6天。预处理方案包括环磷酰胺（CTX）50毫克/千克/天×4天和抗胸腺细胞球蛋白（ATG）10毫克/千克/天×2天。移植了8.97×10⁸个有核细胞/千克、9.20×10⁶个CD34⁺细胞/千克、1.12×10⁵个粒-巨噬细胞集落形成单位（CFU-GM）/千克。
allo-PBSCT后第18天实现造血重建。用三个微卫星标记监测植入情况，第18天显示混合嵌合体，第25天后显示完全嵌合体。未发生急性或慢性移植物抗宿主病（GVHD）。在240天的随访期间，血常规和骨髓象正常，生活状态良好。
allo-PBSCT是治疗急性再生障碍性贫血的有效疗法。
